US FDA approves labeling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia
· Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase of treatment · Approval was based on Rexulti demonstrating efficacy and safety in a long-term randomized withdrawal trial · The trial demonstrated a statistically significant, longer time to relapse in patients treated with Rexulti compared to placebo-treated patients Valby, Denmark and Princeton, New Jersey, 23 September 2016 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) announced today that the US Food and